American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

$Viridian Therapeutics, Inc.\DE logo$

Viridian Therapeutics, Inc.\DE (VRDN)

$19.27 +0.05% NASDAQ: VRDN · 15-min delayed

WALTHAM, Massachusetts
Public · NASDAQ: VRDN
252 employees

Visit website Follow

$1.7BMarket cap

$4.0MRevenue · FY2017

-$342.6MNet income

252Employees

VRDNNASDAQ

2014IPO

About Viridian Therapeutics, Inc.\DE

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: VRDN
Employees: 252
IPO date: Jun 18, 2014
Headquarters: 221 CRESCENT STREET
WALTHAM, Massachusetts 02453
Phone: 617.272.4600
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: VRDN Nasdaq
SEC CIK: 1590750
LEI: 549300C775BNYF550E70
EIN: 471187261
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Embed this company’s badge

Show Viridian Therapeutics, Inc.\DE’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/viridian-therapeutics-incde/"><img src="https://americancompanies.com/badge/viridian-therapeutics-incde.svg" alt="Viridian Therapeutics, Inc.\DE — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Viridian Therapeutics, Inc.\DE and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2017: $4.0M
Net income: -$342.6M
Total assets: $899.4M
Market cap: $1.7B
Operating margin: -512.9%
Net margin: -483.6%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $70.8M
Operating expenses: $434.2M
Operating income: -$363.4M
Income tax: $0
Net income: -$342.6M

Balance sheet

Total assets: $899.4M
Current assets: $894.2M
Total liabilities: $177.3M
Current liabilities: $70.7M
Shareholders’ equity: $722.2M

Cash flow

Operating cash flow: -$276.4M
Investing cash flow: -$37.6M
Financing cash flow: $426.7M
Net cash flow: $112.8M

Statements via Polygon.io (SEC filings)

NASDAQ: VRDN

$19.27 +0.05%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$13.30 $33.78

52-week range

Market cap: $1.7B
Shares outstanding: 90.4M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jun 18, 2014

Viridian Therapeutics, Inc.\DE (VRDN) Stock Price

Reported a net loss of $342.6M in FY2017.
Revenue grew 2291% from FY2021 to FY2025.
Trading 43% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Viridian Therapeutics, Inc.\DE.

Write a review

Newsroom

News about Viridian Therapeutics, Inc.\DE

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million The Motley Fool · 2026-05-17 · neutral Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know The Motley Fool · 2026-04-21 · negative J.Jill, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses GlobeNewswire Inc. · 2026-04-01 · negative Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses GlobeNewswire Inc. · 2026-03-31 · negative Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake The Motley Fool · 2026-02-23 · neutral How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? Benzinga · 2025-12-31 · positive

News & sentiment via Polygon.io

FAQ

Viridian Therapeutics, Inc.\DE: frequently asked questions

Is Viridian Therapeutics, Inc.\DE an American company?

Viridian Therapeutics, Inc.\DE is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Viridian Therapeutics, Inc.\DE headquartered?

Viridian Therapeutics, Inc.\DE is headquartered in Waltham, Massachusetts, United States.

Is Viridian Therapeutics, Inc.\DE publicly traded?

Yes — Viridian Therapeutics, Inc.\DE is a publicly traded company. Its stock trades under the ticker symbol VRDN on the NASDAQ.

What does Viridian Therapeutics, Inc.\DE do?

Viridian Therapeutics, Inc.\DE is an American Pharmaceuticals company in the Health & Beauty sector.

Explore